Loading organizations...
Loading organizations...

Exo Therapeutics: Biotech developing small-molecule therapeutics that reprogram enzyme activity by targeting exosites for oncology and autoimmune diseases.
Exo Therapeutics is a Watertown, Massachusetts-based biotechnology company that develops small-molecule drugs targeting enzyme exosites to treat cancer and autoimmune conditions. The organization utilizes its ExoSight platform to discover specific compounds that selectively reprogram enzyme activity rather than blocking traditional active sites. Operating with a team of fewer than 25 employees, the enterprise has raised $103 million in total funding across two venture capital rounds to support its clinical advancement. This capital includes a $78 million Series B financing round secured in October 2021 to advance four preclinical programs, drawing backing from prominent investors such as Novartis. The firm maintains connections to the broader biopharmaceutical ecosystem through its leadership's ties to related entities like Beam Therapeutics. Exo Therapeutics was founded in 2018 by researchers David R. Liu, Alan Saghatelian, and Juan Pablo Maianti.
Exo Therapeutics has raised $103.0M across 2 funding rounds.
Exo Therapeutics has raised $103.0M in total across 2 funding rounds.
Exo Therapeutics has raised $103.0M in total across 2 funding rounds.
Exo Therapeutics's investors include Thilo Schroeder, Nextech Invest, The Column Group, 6 Dimensions Capital, Kanishka Pothula, Casdin Capital, CRV, Morningside, Newpath Partners, Novartis, Samsara BioCapital, Thomas Cahill.
Exo Therapeutics is a biotechnology company founded in 2018 that develops small molecule drugs targeting exosites on enzymes to treat oncology and inflammatory diseases.[1][2][3][4] Its core ExoSight™ platform identifies and modulates these allosteric binding pockets, enabling precise enzyme inhibition for previously intractable targets, with a pipeline addressing autoimmune diseases and STING-mediated inflammation.[1][3][5] The company has raised $103M total, including a $78M Series B in 2021, and operates from Cambridge, Massachusetts, serving the biopharmaceutical industry with drug discovery services.[1]
Growth momentum includes recent data presentations on EXO-TBKi inhibitors at the American College of Rheumatology’s Convergence, demonstrating disruption of pathological STING-mediated TBK1 activation.[5]
Exo Therapeutics was founded in 2018 in Cambridge, Massachusetts, to tackle the challenge of drugging enzymes in oncology and inflammation that resist traditional active-site inhibitors.[1][3] The idea emerged from recognizing enzymes' exosites—allosteric pockets distinct from active sites—as untapped opportunities for modulation, leading to the creation of the ExoSight™ platform for their identification and targeting.[1][3][4] Early traction came via venture funding, culminating in a $78M Series B round in October 2021 to advance this novel enzyme inhibition approach.[1]
Exo Therapeutics rides the trend of allosteric modulation and precision biotech, shifting from rigid active-site inhibitors to flexible exosite targeting amid rising demand for therapies in oncology, autoimmune, and inflammatory diseases.[1][3] Timing aligns with advances in structural biology and AI-driven drug discovery, amplified by post-2021 funding waves for platform biotech firms.[1] Market forces like unmet needs in STING pathway disorders and enzyme-driven cancers favor its approach, positioning it to influence the ecosystem by validating exosites as a new drug class and partnering with pharma for pipeline expansion.[5]
Exo Therapeutics is poised to advance its pipeline with ExoSight™, potentially delivering first-in-class exosite inhibitors amid growing emphasis on allosteric therapies and inflammation targets like TBK1/STING.[5] Trends in biomarker-driven precision medicine and non-invasive diagnostics will shape its path, with influence evolving through clinical milestones and big pharma collaborations.[1][3] Watch for Phase I data and further funding to solidify its role in unlocking biotech's next frontier, building on its pioneering platform for transformative medicines.[1][5]
Exo Therapeutics has raised $103.0M across 2 funding rounds. Most recently, it raised $78.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $78.0M Series B | Thilo Schroeder | Nextech Invest, The Column Group, 6 Dimensions Capital, Kanishka Pothula, Casdin Capital, CRV, Morningside, Newpath Partners, Novartis, Samsara BioCapital |
| Dec 16, 2020 | $25.0M Series A | 6 Dimensions Capital, CRV, Thomas Cahill, Novartis |